For New Zealand Residents Only

Just one puff, once a day Helps prevent symptoms for a full 24 hours^1-8

Take the test

then talk to your healthcare professional about your result and treatment options to manage your asthma or COPD.

IMPORTANT SAFETY INFORMATION: BREO ELLIPTA, ANORO ELLIPTA, INCRUSE ELLIPTA and TRELEGY ELLIPTA
should not be used to relieve a sudden attack of shortness of breath or wheezing.^2,4,6,8
Any information provided on this site should be discussed with a health care professional (HCP) and does not replace a HCP’s advice.

References: 1. Breo Ellipta Data Sheet, GSK New Zealand, available at www.medsafe.govt.nz (Accessed January 2025) 2. Breo Ellipta Consumer Medicine Information, GSK New Zealand, available at www.medsafe.govt.nz (Accessed January 2025) 3. Anoro Ellipta Data Sheet, GSK New Zealand, available at www.medsafe.govt.nz (Accessed January 2025) 4. Anoro Ellipta Consumer Medicine Information, GSK New Zealand, available at www.medsafe.govt.nz (Accessed January 2025) 5. Incruse Ellipta Data Sheet. GSK New Zealand. Available at www.medsafe.govt.nz. [Accessed August 2024] 6. Incruse Ellipta Consumer Medicine Information. GSK New Zealand. Available at www.medsafe.govt.nz (Accessed January 2025) 7. Trelelgy Ellipta Data Sheet, GSK New Zealand, available at www.medsafe.govt.nz (Accessed January 2025) 8. Trelegy Ellipta Consumer Medicine Information, GSK New Zealand, available at www.medsafe.govt.nz (Accessed January 2025)

Disclaimer: GSK is not responsible for third-party website content.

Anoro Ellipta (umeclidinium (as bromide)/vilanterol (as trifenatate) inhaler, 62.5/25 mcg per dose) is a Prescription Medicine. Anoro Ellipta is used for long-term regular treatment to relieve symptoms in adults with Chronic Obstructive Pulmonary Disease (COPD). Anoro Ellipta is a fully funded medicine for patients with COPD – restrictions apply. Anoro Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack, you must use a quick-acting (reliever) inhaler. Always carry your reliever inhaler. Do not discontinue Anoro Ellipta unless advised by your doctor. If symptoms continue or you have side effects, see your doctor, pharmacist or healthcare professional. Anoro Ellipta has risks and benefits. Use strictly as directed. For more information see Anoro Ellipta Consumer Medicine Information at www.medsafe.govt.nz. Normal doctor’s charges apply. Ask your doctor if Anoro Ellipta is right for you.

Breo Ellipta (fluticasone furoate 100 mcg or 200 mcg)/25 vilanterol (as trifenatate) 25 mcg, powder for inhalation. Breo Ellipta is a Prescription Medicine. Breo Ellipta is used for the regular treatment of asthma (12 years of age and older) and for adults with Chronic Obstructive Pulmonary Disease. (COPD). Breo Ellipta 100/25mcg is a fully funded medicine; Breo Ellipta 200/25mcg is an unfunded medicine for asthma use only. Breo Ellipta is not for relief of acute symptoms; a separate reliever inhaler may be required. Always carry your reliever inhaler. Do not discontinue Breo Ellipta unless advised. Tell your doctor: if you are taking any other medicine, have liver disease, heart problems, high blood pressure, diabetes or high blood sugars, pulmonary tuberculosis (TB), pneumonia or osteoporosis, or you are allergic to either fluticasone furoate or vilanterol or any of the excipients in Breo Ellipta.
Side Effects: Headache, common cold, oral thrush, infection of the sinuses, pneumonia (COPD patients) and weakening of the bones, leading to a risk of fractures. If symptoms continue or you have side effects, see your doctor, pharmacist of health care professional. This Medicine has risks and benefits. Use strictly as directed. For more information see Breo Ellipta Consumer Medicine Information at www.medsafe.govt.nz Normal doctor’s charges apply. Ask your doctor if Breo Ellipta is right for you.

Incruse Ellipta (umeclidinium (as bromide) inhaler, 62.5 mcg per dose) is a Prescription Medicine. Incruse Ellipta is used for long-term regular treatment to relieve symptoms in adults with Chronic Obstructive Pulmonary Disease (COPD). Incruse Ellipta is a fully funded medicine for patients with COPD – restrictions apply. Incruse Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack, you must use a quick-acting (reliever) inhaler. Always carry your reliever inhaler. Do not discontinue Incruse Ellipta unless advised by your doctor. If symptoms continue or you have side effects, see your doctor, pharmacist or healthcare professional. Use strictly as directed. Incruse Ellipta has risks and benefits. For more information see Incruse Ellipta Consumer Medicine Information at www.medsafe.govt.nz. Normal doctor’s charges apply. Ask your doctor if Incruse Ellipta is right for you.

Trelegy Ellipta (fluticasone furoate/umeclidinium [as bromide]/vilanterol [as trifenatate] inhaler100/62.5/25mcg per dose) is a Prescription Medicine. Trelegy Ellipta is used for the regular treatment of adults with asthma or chronic obstructive pulmonary disease (COPD). Trelegy Ellipta 100/62.5/25mcg is fully funded for patients with COPD only; Special Authority criteria apply. Use strictly as directed. Trelegy Ellipta has risks and benefits. Trelegy Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack, you must use a quick-acting (reliever) inhaler. Always carry your reliever inhaler. Do not discontinue Trelegy Ellipta unless advised by your doctor. If symptoms continue or you have side effects, see your doctor, pharmacist or healthcare professional. For more information see Trelegy Ellipta Consumer Medicine Information at www.medsafe.govt.nz. Ask your doctor if Trelegy Ellipta is right for you. Normal doctor’s charges apply.

Anoro Ellipta, Breo Ellipta and Incruse Ellipta were developed in collaboration with Innoviva Inc. Trademarks are owned by or licensed to the GSK group of companies. ©2025 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS NP22045-PM-NZ-UCV-WCNT-240005 Date of Approval: 03 2025 Date of Expiry: 03 2027

Just one puff, once a day Helps prevent symptoms for a full 24 hours^1-8

Take the test

then talk to your healthcare professional about your result and treatment options to manage your asthma or COPD.

Asthma

COPD Test

Just one puff, once a day Helps prevent symptoms for a full 24 hours1-8

Take the test

then talk to your healthcare professional about your result and treatment options to manage your asthma or COPD.

Asthma

COPD Test

Just one puff, once a day Helps prevent symptoms for a full 24 hours^1-8